Candriam S.C.A. Rigel Pharmaceuticals Inc Transaction History

Candriam S.C.A.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$2.22 - $3.45 $1.76 Million - $2.73 Million	-792,066 Reduced 35.65%	1,429,630 $4.27 Million
Q2 2021 Jul 20, 2021	BUY	$3.09 - $4.54 $6.87 Million - $10.1 Million	2,221,696 New	2,221,696 $9.64 Million
Q4 2020 Jan 22, 2021	SELL	$2.35 - $3.74 $658,000 - $1.05 Million	-280,000 Closed	0 $0
Q3 2020 Oct 19, 2020	SELL	$1.78 - $4.13 $2.96 Million - $6.87 Million	-1,663,000 Reduced 85.59%	280,000 $672,000
Q2 2020 Jul 23, 2020	SELL	$1.41 - $2.05 $705,000 - $1.02 Million	-500,000 Reduced 20.47%	1,943,000 $3.56 Million
Q4 2019 Jan 21, 2020	SELL	$1.6 - $2.43 $56,000 - $85,050	-35,000 Reduced 1.41%	2,443,000 $5,000
Q3 2019 Oct 21, 2019	SELL	$1.63 - $2.62 $12,143 - $19,519	-7,450 Reduced 0.3%	2,478,000 $5,000
Q2 2019 Aug 01, 2019	BUY	$2.02 - $2.61 $15,049 - $19,444	7,450 Added 0.3%	2,485,450 $14.3 Million
Q4 2018 Feb 14, 2019	BUY	$2.08 - $3.36 $436,800 - $705,600	210,000 Added 9.26%	2,478,000 $5.7 Million
Q3 2018 Nov 07, 2018	BUY	$2.6 - $3.59 $1.81 Million - $2.51 Million	698,000 Added 44.46%	2,268,000 $7.28 Million
Q2 2018 Aug 14, 2018	BUY	$2.83 - $4.11 $183,950 - $267,150	65,000 Added 4.32%	1,570,000 $4.44 Million
Q1 2018 May 09, 2018	BUY	$3.54 - $4.54 $1.01 Million - $1.29 Million	285,000 Added 23.36%	1,505,000 $5.33 Million
Q4 2017 Feb 07, 2018	SELL	$3.23 - $4.3 $145,350 - $193,500	-45,000 Reduced 3.56%	1,220,000 $4.73 Million
Q3 2017 Nov 03, 2017	BUY	$2.18 - $2.57 $2.76 Million - $3.25 Million	1,265,000	1,265,000 $3.21 Million

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.84B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.